Resistance to Chemotherapy and Targeted Therapy in Cancer: Understanding the Pathogenesis and Identifying the Best Approaches to Overcome This Challenge
A special issue of Current Oncology (ISSN 1718-7729).
Deadline for manuscript submissions: 31 May 2025 | Viewed by 156
Special Issue Editor
Special Issue Information
Dear Colleagues,
While surgery and radiotherapy are the primary treatments used for local cancers, systemic therapy, whether chemotherapy, immunotherapy, targeted therapy, or hormonal therapy, is the cornerstone in the management of advanced cancers. Despite all the advancements that we have made in cancer treatment, there are still many challenges that face us. One of the main challenges that we face is resistance to therapy. Resistance to chemotherapy has been a challenge in cancer therapy for a long time. During the recent two decades, novel therapies targeting the genomic drivers of cancer development and the tumor microenvironment and immunological environment have been adopted with huge success. Examples of these therapies include HER2 targeted therapy in breast cancer, EGFR inhibitors in lung cancer, and anti-CTLA and anti-PD-1/PD-L1 monoclonal antibodies in many tumors. However, regardless of all of these advancements, resistance to therapy remains a huge challenge. For this Special Issue, we welcome manuscripts that focus on understanding drug resistance in cancer, its pathogenesis, and describe new approaches and advances in medicine that can help prevent or delay resistance to therapy. We also welcome original research and economic evaluation on this relevant topic.
Dr. Oudai Hassan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chemotherapy
- targeted therapy
- resistance
- microenvironment
- immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
